Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B, Benekli M, Turker I, Koral L, Ulas A, Dane F, Oksuzoglu B, Kaplan MA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Cetin B, et al. Among authors: ulas a. J Chemother. 2014 Oct;26(5):300-5. doi: 10.1179/1973947813Y.0000000147. Epub 2013 Dec 6. J Chemother. 2014. PMID: 24112786
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Cetin B, Benekli M, Oksuzoglu B, Koral L, Ulas A, Dane F, Turker I, Kaplan MA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Isıkdogan A, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Cetin B, et al. Among authors: ulas a. Onkologie. 2012;35(12):740-5. doi: 10.1159/000345040. Epub 2012 Oct 31. Onkologie. 2012. PMID: 23207619 Free article.
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO, Büyükberber S, Ozkan M, Alkiş N, Sevinc A, Ozdemir NY, Alici S, Esbah O, Berk V, Camci C, Ulas A, Coskun U, Benekli M; Anatolian Society of Medical Oncology (ASMO). Kaya AO, et al. Among authors: ulas a. Asian Pac J Cancer Prev. 2012;13(2):463-7. doi: 10.7314/apjcp.2012.13.2.463. Asian Pac J Cancer Prev. 2012. PMID: 22524807 Free article.
Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology.
Uyeturk U, Oksuzoglu B, Akman T, Turker I, Sener N, Tastekin D, Bal O, Berk V, Arslan UY, Urakci Z, Bilir C, Yilmaz U, Yazilitas D, Ulas A, Sonmez OU, Budakoglu B, Cihan S, Uysal M. Uyeturk U, et al. Among authors: ulas a. Med Oncol. 2014 Apr;31(4):929. doi: 10.1007/s12032-014-0929-0. Epub 2014 Mar 22. Med Oncol. 2014. PMID: 24659267
Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, Yazilitas D, Ulas A, Kucukoner M, Aksoy A, Demirci U, Uysal M, Tanriverdi O, Gunaydin Y, Sumbul AT, Yildiz R, Karaca H, Oksuzoglu B, Ciltas A, Buyukberber S, Benekli M; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: ulas a. Breast. 2016 Feb;25:22-6. doi: 10.1016/j.breast.2015.11.006. Epub 2015 Dec 20. Breast. 2016. PMID: 26801412
Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N, Benekli M, Koca D, Ustaalioglu BO, Dane F, Ozdemir N, Ulas A, Oztop I, Gumus M, Ozturk MA, Berk V, Kucukoner M, Uner A, Balakan O, Helvaci K, Ozkan S, Yilmaz U, Buyukberber S; Anatolian Society of Medical Oncology. Turan N, et al. Among authors: ulas a. Oncology. 2013;84(1):14-21. doi: 10.1159/000342429. Epub 2012 Oct 16. Oncology. 2013. PMID: 23076023
Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S. Tonyali O, et al. Among authors: ulas a. Onkologie. 2013;36(10):554-8. doi: 10.1159/000355156. Epub 2013 Sep 16. Onkologie. 2013. PMID: 24107908
Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.
Elkiran ET, Kaplan MA, Sevinc A, Aksoy S, Demirci U, Seker M, Harputluoglu H, Ozdemir NY, Isik F, Ulas A, Inanc M, Arslan UY, Dogu GG, Isikdogan A, Buyukberber S; Anatolian Society of Medical Oncology Group. Elkiran ET, et al. Among authors: ulas a. Med Oncol. 2012 Dec;29(5):3147-54. doi: 10.1007/s12032-012-0276-y. Epub 2012 Jun 22. Med Oncol. 2012. PMID: 22722923
Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Bozkurt O, Inanc M, Hacibekıroglu I, Esbah O, Seker M, Ulas A, Aydin K, Uysal M, Kücüköner M, Uncu D, Cıltas A, Unal OÜ, Durnali A, Demırcı U, Berk V, Tonyali O, Oksüzoglu B, Karaca H, Ozkan M. Bozkurt O, et al. Among authors: ulas a. Anticancer Res. 2014 Aug;34(8):4463-70. Anticancer Res. 2014. PMID: 25075086
121 results